AMGN
Amgen Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -5.0% ·
share flow +0.2% ·
net new positions -5.3%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.52M | $603.13M | n/a | −2 |
| Q2 2026 | 169 | -1 | 364.70M | $131.99B | +5 | −7 |
| Q1 2026 | 174 | -2 | 366.40M | $128.82B | +4 | −7 |
| Q4 2025 | 175 | 0 | 394.29M | $128.98B | +2 | −1 |
| Q3 2025 | 26 | 0 | 206.42M | $58.23B | n/a | −1 |
| Q2 2025 | 24 | +1 | 183.25M | $51.15B | +2 | −1 |
| Q1 2025 | 20 | -2 | 81.79M | $25.47B | n/a | −2 |
| Q4 2024 | 22 | +2 | 74.78M | $19.48B | +2 | n/a |
| Q3 2024 | 19 | -1 | 39.65M | $12.76B | +1 | −2 |
| Q2 2024 | 20 | n/a | 39.58M | $12.36B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 14.26M | -1.3% | $4.59B | 3.4% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 12.12M | +0.9% | $3.89B | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 5.80M | -0.1% | $1.87B | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 4.55M | +0.6% | $1.46B | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 705.11K | +7.4% | $227.19M | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 601.66K | +4.0% | $193.86M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 7 | Capital World Investors ✦ | 466.65K | New | $150.36M | 0.0% | New | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 358.74K | -33.8% | $115.59M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 239.35K | +2.1% | $77.12M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 10 | D. E. Shaw & Co. ✦ | 166.45K | -45.7% | $53.63M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 120.74K | +65.1% | $38.75M | 0.1% | ▲ Add | 2 | SEC ↗ ×3 |
| 12 | Fisher Asset Management ✦ | 102.35K | +21.3% | $32.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | ARK Investment Management ✦ | 76.61K | +2.4% | $24.69M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 14 | Millennium Management ✦ | 30.01K | -55.3% | $9.67M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 21.41K | -3.3% | $6.90M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 16 | Dodge & Cox ✦ | 14.28K | -0.7% | $4.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 7.80K | -65.8% | $2.51M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 5.25K | -6.2% | $1.69M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 3.37K | -61.4% | $1.09M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Capital World Investors | $150.36M | 0.0% |
Exited
| Renaissance Technologies | $16.32M | was 0.0% |
| Arrowstreet Capital | $11.65M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3,100 holders, 420.54M shares, $144.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.25K sh · $521,365
Officer · 2.00K sh · $825,134
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology